GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsBio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceuticalcompany, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for BAT1706, a proposed biosimilar to Avastin®(bevac...
has reached a licensing agreement with for BAT06, its biosimilar, under which will have exclusive rights to distribute and market the drug in BATis a proposed biosimilar for the treatment of Bio-Thera’s BAT1706 has successfully completed a global Pha...
GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceuticalcompany, today announced that it has submitted the MAA for BAT1706, a proposed biosimilar to Avastin® (bevacizumab), to EMA. Bio-Thera seeks a c...
